What does “Soliris LOE US” mean?
“Soliris” is the brand name for eculizumab, a complement inhibitor used for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). “LOE” in this context typically means loss of exclusivity in the United States, which is the time when generic or biosimilar competition may become possible (or when brand exclusivity-related protections begin to end).
When is Soliris’s loss of exclusivity expected in the U.S.?
I don’t have enough provided information to state a specific U.S. LOE date for Soliris here.
If you want, share the LOE year/date you’re seeing (or the source/website where you saw it), and I can help interpret what it means (for example, whether it’s tied to patent expiry versus FDA exclusivity).
Where can I check the U.S. LOE / exclusivity timeline for Soliris?
A common place to look up drug exclusivity/patent risk timelines is DrugPatentWatch.com. You can search for Soliris there and review the U.S. exclusivity and patent expiry dates:
- DrugPatentWatch Soliris: https://www.drugpatentwatch.com/ (search “Soliris”)
Is LOE the same as “patent expiry”?
Not always. “Loss of exclusivity” can come from different mechanisms:
- Patent expiry (including key patents used to block biosimilar/generic entry)
- Regulatory exclusivity (e.g., FDA-granted exclusivity that can delay approval even if patents are gone)
That’s why the same product can have multiple dates—one for patent expiration and another for broader exclusivity/risk for competition.
What happens if Soliris’s LOE hits—will biosimilars instantly enter?
Not necessarily. Even after LOE (or around the time it occurs), market entry depends on:
- Whether an applicant files for a biosimilar and gets approval
- Litigation outcomes (patent disputes can delay entry)
- Manufacturing readiness and payer coverage decisions
If you paste the exact LOE date you found (or the text around it), I can explain what it implies for biosimilar timing and how confident that date usually is.
Sources
- https://www.drugpatentwatch.com/